Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Pajtler, KW; Tippelt, S; Siegler, N; Reichling, S; Zimmermann, M; Mikasch, R; Bode, U; Gnekow, A; Pietsch, T; Benesch, M; Rutkowski, S; Fleischhack, G.
Intraventricular etoposide safety and toxicity profile in children and young adults with refractory or recurrent malignant brain tumors.
J Neurooncol. 2016; 128(3):463-471
Doi: 10.1007/s11060-016-2133-x
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Benesch Martin
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Systemic administration of etoposide is effective in treating metastatic, recurrent or refractory brain tumors, but penetration into the cerebrospinal fluid is extremely poor. This study was designed to determine the safety and toxicity profile of intraventricular etoposide administration and was affiliated with the prospective, multicenter, nonblinded, nonrandomized, multi-armed HIT-REZ-97 trial. The study enrolled 68 patients, aged 1.1-34.6 (median age 11 years). Adverse events that could possibly be related to intraventricular etoposide therapy were documented and analyzed. Intraventricular etoposide was simultaneously administered with either oral or intravenous chemotherapy in 426 courses according to three major schedules varying in dosing (0.25-1 mg), frequency of administration (bolus injection, every 12 or 24 h), course duration (5-10 days) and length of interval between courses (2-5 weeks). Potential treatment-related adverse effects included transient headache, seizures, infection of the reservoir, nausea and neuropsychological symptoms. Hematological side effects were not observed. One patient, with history of multiple prior therapies, who received long-term intraventricular and oral etoposide treatment developed acute myeloid leukemia as a secondary malignancy. Overall intraventricular etoposide is well tolerated. The results of this study have warranted a phase II trial to determine the effectiveness of this regimen in disease stages with very limited therapeutic options.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Adult -
- Antineoplastic Agents, Phytogenic - administration & dosage
- Antineoplastic Agents, Phytogenic - adverse effects
- Brain Neoplasms - drug therapy
- Cerebral Ventricles -
- Child -
- Child, Preschool -
- Drug Therapy, Combination -
- Etoposide - administration & dosage
- Etoposide - adverse effects
- Female -
- Follow-Up Studies -
- Humans -
- Infant -
- Male -
- Treatment Outcome -
- Young Adult -
- Find related publications in this database (Keywords)
- Ependymoma
- Medulloblastoma
- ATRT
- Relapse
- Progression
- Pediatric brain tumors